DRD2: A Potential Drug Target for Psychiatric Disorders (P5809)

Target Name: Dopamine receptor

NCBI ID: P5809

Dopamine receptor

Other Name(s): None

DRD2: A Potential Drug Target for Psychiatric Disorders

Dopamine receptor (DR) is a family of transmembrane proteins that play a crucial role in various physiological processes in the brain, including motivation, pleasure, and mood regulation. The DR family consists of seven subtypes, each with distinct functions and gene expression patterns. One of the DR subtypes, named DRD2, has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders.

DRD2 is a type I transmembrane receptor that is expressed in the brain and other tissues. It is characterized by a long N-terminal region, a transmembrane region, and an intracellular region. The N-terminal region contains a protein called D2R1, which is a key receptor for dopamine (D2) agonists. The transmembrane region contains a unique carboxylic acid residue at its end, which is involved in ligand binding. The intracellular region contains several unique protein tyrosine residues, including a Glu-342, which is involved in G protein-coupled receptor (GPCR) signaling.

DRD2 has been shown to play a role in various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. Studies have shown that individuals with major depressive disorder (MDD) have lower levels of DRD2 than healthy controls, and that treatment with dopamine agonists , such as selective serotonin reuptake inhibitors (SSRIs), can increase DRD2 levels in individuals with MDD. Similarly, individuals with anxiety and depression have lower levels of DRD2 than healthy controls, and that treatment with dopamine agonists can increase DRD2 levels in these individuals.

In addition to its role in psychiatric disorders, DRD2 has also been shown to play a role in neurological disorders, including Parkinson's disease and Huntington's disease. Studies have shown that individuals with Parkinson's disease have lower levels of DRD2 than healthy controls, and that dopamine agonists can increase DRD2 levels in these individuals. Similarly, individuals with Huntington's disease have lower levels of DRD2 than healthy controls, and that dopamine agonists can increase DRD2 levels in these individuals.

DRD2 has also been shown to play a role in motivation and pleasure. Studies have shown that individuals with ADHD have lower levels of DRD2 than healthy controls, and that dopamine agonists can increase DRD2 levels in these individuals. Similarly, individuals with narcissistic personality disorders have lower levels of DRD2 than healthy controls, and that dopamine agonists can increase DRD2 levels in these individuals.

In addition to its role in psychiatric and neurological disorders, DRD2 has also been shown to play a role in various physiological processes in the brain. Studies have shown that DRD2 is involved in the regulation of neuronal excitability, and that it plays a role in the development and maintenance of synaptic plasticity. Additionally, DRD2 is involved in the regulation of neurotransmitter release and uptake, and is therefore thought to play a role in the regulation of mood and emotion.

In conclusion, DRD2 is a protein that has been shown to play a role in various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. Studies have shown that individuals with MDD, anxiety, and depression have lower levels of DRD2 than healthy controls , and that dopamine agonists can increase DRD2 levels in these individuals. Additionally, DRD2 has also been shown to play a role in various physiological processes in the brain, including the regulation of neuronal excitability and the regulation of neurotransmitter release and uptake. These findings suggest that DRD2 may be a promising drug target

Protein Name: Dopamine Receptor (nonspecified Subtype)

The "Dopamine receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Dopamine receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets